The losses, liquidations and curious ties of Link s shock Woodford investment citywire.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citywire.co.uk Daily Mail and Mail on Sunday newspapers.
TRADING UPDATES: Arix backs buyback; 88 Energy notes share price surge
Mon, 15th Mar 2021 21:44
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Arix Bioscience PLC - focused on investing in biotech companies - Says board approves buyback of up to GBP25 million worth of shares. The share buyback programme is consistent with Arix s strategy of creating and delivering value for all stakeholders and follows shareholder consultation as part of the company s stated commitment to keep use of cash under review, following the trade sale of VelosBio, Arix says.
EXECUTIVE CHANGES: Marlowe Poaches From Fullers; RM Promotes To CEO
Fri, 26th Feb 2021 17:14
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and Friday and not separately reported by Alliance News:
Marlowe PLC - London-based safety and compliance services and software - Hires Adam Councell as chief financial officer. Councell is finance director of pub and hotel chain Fuller, Smith & Turner PLC. Fullers says that Councell will stay on the board as finance director until a successor has been found and that a search is underway. Marlowe says Councell will join in the second half of its 2022 financial year, meaning October 2021 to March 2022. Councell was CFO at document management company Restore PLC, where he worked with Marlowe Chief Executive Alex Dacre. Prior to that, he was with pest control firm Rentokil Initial PLC. At Marlowe, Councell will replace Mark Adams, who is retiring.
Immunocore Prices NASDAQ IPO The Company (LSE: SUPP) is pleased to announce that its portfolio company Immunocore Holdings plc ( Immunocore ) has announced the pricing of its initial public offering ( IPO ) of 9,935,896 American Depositary Shares ( ADSs ) representing 9,935,896 ordinary shares at an IPO price of $26.00 per ADS, for total gross proceeds of approximately $258.3 million. Immunocore also raised $15 million in a concurrent private placement. Immunocore s ADSs are expected to begin trading on The Nasdaq Global Select Market ( NASDAQ ) on February 5, 2021 under the ticker symbol IMCR. In addition, Immunocore has granted the underwriters a 30-day option to purchase up to an additional 1,490,384 ADSs at the initial public offering price, less underwriting discounts and commissions.
Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, as-is , and you use it at your own risk. The contents of all Chat messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates. London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.